• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

AntriaBio raises $13m for injectable, once-weekly insulin

July 17, 2017 By Sarah Faulkner

AntriaBioAntriaBio (OTC:ANTB) said today that it closed a $13 million private placement, supported by Aju Pharm, Ildong Pharmaceutical Co. and Medici Investment Co.

According to the deal, investors paid $1.00 per share of common stock.

The Louisville, Colo.-based company said it plans to use the proceeds for general corporate purposes, including the Phase I study of its injectable, once-weekly basal insulin. AntriaBio added that the funds are slated to support pipeline candidates for patients with Type I and Type II diabetes.

In June, the company filed an investigational new drug application with the FDA for AB101. AntriaBio said the IND became effective without hold on July 1 and it expects to dose the 1st patient with AB101 before the end of the month.

Preclinical studies of AB101 have shown comparable activity to regular human insulin. The company said it has not seen acute or delayed sudden increases of insulin in its preclinical work.

The company’s studies also suggest that an ultra long-lasting insulin may stabilize endogenous insulin-glucose homeostasis and lessen fluctuations in blood sugar levels, AntriaBio reported.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Featured, Food & Drug Administration (FDA), Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: antriabio

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS